Researchers have unveiled promising data on a new treatment called STX-1150, which could significantly lower bad cholesterol levels. In tests on non-human primates, a single dose of this investigational therapy led to reductions in low-density lipoprotein cholesterol (LDL-C) by as much as 68% and a nearly 90% drop in a related protein, PCSK9. Remarkably, even the lowest dose maintained over a 50% reduction in LDL-C for more than 22 months, suggesting a long-lasting effect that could benefit people struggling with high cholesterol.

This finding is particularly relevant for individuals looking to manage their cholesterol levels and improve heart health. Elevated LDL-C is a major risk factor for cardiovascular diseases, which can lead to serious health issues as we age. If STX-1150 proves effective in humans, it could offer a new, long-acting option for those needing to lower their cholesterol without the need for daily medication, potentially making it easier for people to maintain their heart health over time.

Currently, STX-1150 is in the early stages of clinical trials, specifically a Phase 1 study involving adults with elevated LDL-C levels. While the preclinical results are promising, they are not yet proven in humans. The treatment has received regulatory clearance in Australia, and enrollment for the study is underway. As research continues, it’s important to remain hopeful but cautious about the potential of this new therapy.

Source: longevity.technology